On Monday, Janux Therapeutics Inc (NASDAQ: JANX) opened higher 18.34% from the last session, before settling in for the closing price of $47.39. Price fluctuations for JANX have ranged from $5.65 to $58.69 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 32.66%. Company’s average yearly earnings per share was noted -13.64% at the time writing. With a float of $34.43 million, this company’s outstanding shares have now reached $46.25 million.
Let’s determine the extent of company efficiency that accounts for 64 employees.
Janux Therapeutics Inc (JANX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Janux Therapeutics Inc is 33.35%, while institutional ownership is 57.73%. The most recent insider transaction that took place on Nov 13 ’23, was worth 4,988,643. In this transaction 10% Owner of this company bought 849,854 shares at a rate of $5.87, taking the stock ownership to the 849,854 shares. Before that another transaction happened on Nov 13 ’23, when Company’s Acting Chief Financial Officer bought 849,854 for $5.87, making the entire transaction worth $4,988,643. This insider now owns 849,854 shares in total.
Janux Therapeutics Inc (JANX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -13.64% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Check out the current performance indicators for Janux Therapeutics Inc (JANX). In the past quarter, the stock posted a quick ratio of 26.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 358.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.64 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Looking closely at Janux Therapeutics Inc (NASDAQ: JANX), its last 5-days average volume was 0.79 million, which is a jump from its year-to-date volume of 0.76 million. As of the previous 9 days, the stock’s Stochastic %D was 43.05%. Additionally, its Average True Range was 4.30.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 90.75%, which indicates a significant increase from 78.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.02% in the past 14 days, which was lower than the 207.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.50, while its 200-day Moving Average is $17.27. However, in the short run, Janux Therapeutics Inc’s stock first resistance to watch stands at $62.19. Second resistance stands at $68.31. The third major resistance level sits at $75.61. If the price goes on to break the first support level at $48.77, it is likely to go to the next support level at $41.47. Now, if the price goes above the second support level, the third support stands at $35.35.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
There are currently 51,660K shares outstanding in the company with a market cap of 2.90 billion. Presently, the company’s annual sales total 8,080 K according to its annual income of -58,290 K. Last quarter, the company’s sales amounted to 2,460 K and its income totaled -11,760 K.
